What Fragment 176-191 Is
Fragment 176-191 corresponds to the C-terminal sequence of human growth hormone (hGH). Researchers at Monash University found in 1993 that this segment alone could reproduce part of the metabolic effect of full-length growth hormone — specifically its ability to suppress fat formation — without carrying the impact on insulin sensitivity that is problematic with full growth hormone treatment. Published clinical studies in humans were conducted with a stabilized synthetic version of this sequence (designated AOD9604), developed for better stability during manufacturing and storage.
Interest in this particular segment of the growth hormone molecule stems from the fact that full-length hormone has a wide range of effects on the body — beyond supporting fat metabolism, it also affects tissue growth, blood sugar levels, and IGF-1 production. The goal of the research was to find the portion of the molecule that carried only the metabolic, "fat" component of the effect, without the rest of the complex hormonal profile. Fragment 176-191 was identified as the smallest functional unit for which this separation could be demonstrated under laboratory conditions, and it became the starting point for further pharmacological development in this direction.
How Fragment 176-191 Works
The mechanism of action is concentrated at the level of fat cells (adipocytes). The molecule binds to beta-3 adrenergic receptors on the surface of fat cells, which activates the enzyme adenylate cyclase and raises intracellular cAMP levels. This signal then activates hormone-sensitive lipase, an enzyme that breaks down stored triglycerides into free fatty acids and glycerol — a process called lipolysis. At the same time, the molecule dampens the activity of lipogenic enzymes such as acetyl-CoA carboxylase, which theoretically also limits new fat formation.
The key difference from full growth hormone is that Fragment 176-191 doesn't compete for binding to the growth hormone receptor, so it doesn't raise IGF-1 levels or affect insulin sensitivity. This separation of the metabolic effect from the side effects associated with the full hormone is the main reason the molecule is studied on its own.
Interestingly, preclinical experiments suggest this mechanism works selectively depending on the organism's state — in obese animals with excess fat tissue, the lipolytic effect was clearly measurable, while in lean animals of normal body weight, the effect was minimal or absent. This is consistent with the observation that levels of the natural lipolytic growth hormone fragment tend to be reduced in obese individuals, so supplementing this signaling pathway externally would theoretically matter more for people with excess weight than for a lean population.
Pharmacokinetically, Fragment 176-191 is among the shorter peptides with relatively rapid metabolic clearance from the body. This is consistent with how the compound was administered in published clinical trials — as a repeated daily dose, not as a single application with a long-lasting effect. This profile is typical of peptides aimed at acute stimulation of a specific signaling pathway, rather than compounds expected to produce a sustained effect between doses.
Clinical Studies: What the Data Show
Preclinical experiments in animal models showed consistent reductions in body fat in obese animals, with a markedly weaker or absent effect in lean animals. Clinical studies in humans, however, were not conducted with Fragment 176-191 itself but with its modified version, AOD9604. The human results in the table below therefore concern AOD9604 and cannot be directly transferred to the fragment itself.
| Study | Design | Finding |
|---|---|---|
| Preclinical models (obese mice and rats) | Chronic administration in obese and lean animal models | 12–23% reduction in body fat in obese animals; minimal effect in lean animals |
| Phase II in humans, AOD9604 (Herd, Wittert, et al., 2005) | 300 obese patients, oral administration, 12 weeks, multiple dose levels | The 1 mg dose group lost an average of 2.8 kg versus 0.8 kg for placebo; improved glucose tolerance and cholesterol profile |
| Phase IIb, the OPTIONS study (AOD9604) | 536 obese adults, 24 weeks, with a structured diet and exercise regimen | No statistically significant difference in weight loss versus placebo |
Preclinical data comes primarily from rodent experiments, where preservation of lean muscle mass alongside a reduction in fat tissue was also observed — a metabolically desirable combination, since many other approaches to weight reduction lead to loss of both fat and muscle mass simultaneously. Whether this specific finding translates into human clinical practice, however, hasn't been separately confirmed in any of the published human studies, which is an important distinction from the overall weight-loss results described in the table below.
The difference between the Phase II and Phase IIb results is a good example of why, with research compounds, it's important to look at the full body of available data rather than a single study — smaller early trials generally tend toward greater variability in results, which only a larger and more rigorously designed study can reliably confirm or rule out.
It's also worth noting that the OPTIONS study included a structured diet and exercise program for all participants, including the placebo group. This more rigorous design may have contributed to leveling out differences between groups that were apparent in the less controlled Phase II trial. The molecule has also been studied outside the area of body weight — for example, in a preclinical osteoarthritis model in rabbits testing intra-articular administration — but this line of research remains at the preclinical stage for now.
Safety Profile
Human safety data come from six randomized controlled trials of AOD9604 in more than 500 participants (Stier et al.). No separate human studies of Fragment 176-191 have been published.
| Parameter | Finding for Fragment 176-191 | For Comparison: Full Growth Hormone |
|---|---|---|
| Rate of adverse effects | Comparable to placebo across trials | Higher rate of adverse effects linked to metabolic changes |
| IGF-1 level | No effect | Raises IGF-1 levels |
| Glucose tolerance / insulin sensitivity | No negative effect | Can impair glucose tolerance and insulin sensitivity |
| Immunogenicity | No antibodies to the compound detected in any trial | Not reported as a comparable issue |
This combination of findings for AOD9604 — adverse events at the placebo level and no effect on IGF-1 or glucose metabolism — is unusually favorable from a safety standpoint compared with other peptides affecting hormonal axes. Low immunogenicity (no antibodies detected against the compound in any trial) further suggests that repeated administration shouldn't lead to a loss of effect due to an immune response, a relevant question for synthetic peptides administered long-term.
The safety review covered both intravenous and oral routes of administration, providing a fairly broad picture of the compound's tolerability across different modes of delivery. Trials also tracked longer-term administration on the order of weeks, not just a single exposure, which increases the informational value of the findings for real-world research and laboratory use.
Forms Used in Research
In laboratory and clinical research, Fragment 176-191 occurs in two main forms — as a lyophilized powder in injection vials (ampoules) intended for reconstitution, or as a ready-to-use liquid in prefilled pens (auto-injectors). Published clinical trials additionally tested an oral form of administration.
| Parameter | Lyophilized Powder in a Vial (Ampoule) | Prefilled Pen (Auto-Injector) |
|---|---|---|
| Physical state | Dry, freeze-dried powder | Ready-to-use liquid solution |
| Preparation required before use | Requires reconstitution — most commonly dissolved in bacteriostatic water | None — the system is ready for immediate use |
| Storage stability | High stability in dry form, longer shelf life | When stored refrigerated (2–8 °C), usable for a period of months |
| Typical use in research | Laboratory and earlier-stage experimental work | Standardized repeated dosing within study protocols |
The choice between the individual forms relates to the research phase and the goal of the specific experiment. While the oral form was historically used in the key clinical trials (including both the Phase II and Phase IIb trials described above), in laboratory settings and more recent research the peptide is typically administered by injection, since oral administration of peptide compounds generally requires higher doses due to partial digestion in the gastrointestinal tract.
This resistance to digestive enzymes, which is what allowed Fragment 176-191 to be tested in oral form at all, is fairly unusual among peptides — most peptide compounds largely break down before being absorbed into the bloodstream when taken orally, which is why injectable administration is generally preferred for them.
Summary
Fragment 176-191 is a peptide with a clearly defined mechanism of action at the fat-cell level — it activates lipolysis via beta-3 adrenergic receptors without affecting IGF-1 levels or insulin sensitivity, distinguishing it from full growth hormone. Human clinical studies concern its modified version, AOD9604: six randomized trials in more than 500 participants showed adverse events at the placebo level and no detected immunogenicity, but results on body weight differed — an early Phase II trial showed a positive result, while a larger Phase IIb trial did not confirm a difference versus placebo. No human studies have been published for Fragment 176-191 itself. In research, the molecule occurs both as a lyophilized powder in vials and in prefilled pens, with the choice of form typically matching the specific purpose of the experiment or study protocol.
Sources
- Wu SH, Ng LT, et al. Preclinical characterization of the C-terminal fragment of human growth hormone, 1993.
- Herd C, Wittert G, Caterson L, Proietto J, Strauss B, Prins J, Stocks A, Vos E, Belyea C. "The effect of AOD9604 on weight loss in obese adults: Results of a randomized, double-blind, placebo-controlled, multicenter study," 2005.
- Stier H, et al. "Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans." Journal of Endocrinology and Metabolism.
- Metabolic Pharmaceuticals Limited — public announcements on the Phase IIb OPTIONS study, 2006–2007.